Loss of Lean Body Mass as an Independent Risk Factor for Continuation of S-1 Adjuvant Chemotherapy for Gastric Cancer
- 17 December 2014
- journal article
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 22 (8), 2560-2566
- https://doi.org/10.1245/s10434-014-4296-z
Abstract
Background and Aims Compliance with S-1 adjuvant chemotherapy is not satisfactory, and the aim of the present study was to clarify risk factors for the continuation of S-1 after gastrectomy.Keywords
This publication has 22 references indexed in Scilit:
- Usefulness of enhanced recovery after surgery protocol as compared with conventional perioperative care in gastric surgeryGastric Cancer, 2011
- Sarcopenia as a Determinant of Chemotherapy Toxicity and Time to Tumor Progression in Metastatic Breast Cancer Patients Receiving Capecitabine TreatmentClinical Cancer Research, 2009
- Long-Term Benefits of Roux-en-Y Pouch Reconstruction After Total GastrectomyAnnals of Surgery, 2008
- Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral FluoropyrimidineNew England Journal of Medicine, 2007
- Body Composition as an Independent Determinant of 5-Fluorouracil–Based Chemotherapy ToxicityClinical Cancer Research, 2007
- Postoperative Changes in Body Composition After GastrectomyJournal of Gastrointestinal Surgery, 2005
- Segmental bioelectrical impedance analysisCurrent Opinion in Clinical Nutrition and Metabolic Care, 2003
- Lean Body Mass as a Predictor of Drug DosageClinical Pharmacokinetics, 1994
- The Meaning and Measurement of Lean Body MassNutrition Reviews, 1991
- Dose-Response Effect of Adjuvant Chemotherapy in Breast CancerNew England Journal of Medicine, 1981